Allogene Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
ALLO$1.06+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $51,039 | $83,155 |
| Short-term investments | 333,821 | 365,542 |
| Prepaid expenses and other current assets | 10,504 | 10,418 |
| Total current assets | 395,364 | 459,115 |
| Long-term investments | 12,405 | — |
| Operating lease right-of-use asset | 64,483 | 63,703 |
| Property and equipment, net | 95,931 | 99,478 |
| Restricted cash | 10,292 | 10,292 |
| Other long-term assets | 5,159 | 6,604 |
| Equity method investments | 2,716 | 3,645 |
| Total assets | $586,350 | $642,837 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $5,779 | $5,897 |
| Accrued and other current liabilities | 25,029 | 31,096 |
| Deferred revenue | 86 | 86 |
| Total current liabilities | 30,894 | 37,079 |
| Lease liability, noncurrent | 88,916 | 88,346 |
| Other long-term liabilities | 5,173 | 5,179 |
| Total liabilities | 124,983 | 130,604 |
| Commitments and Contingencies (Notes 6 and 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares were issued and outstanding as of March 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.001 par value: 400,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 170,452,967 and 168,642,238 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 170 | 169 |
| Additional paid-in capital | 2,089,357 | 2,075,252 |
| Accumulated deficit | (1,627,233) | (1,562,233) |
| Accumulated other comprehensive loss | (927) | (955) |
| Total stockholders’ equity | 461,367 | 512,233 |
| Total liabilities and stockholders’ equity | $586,350 | $642,837 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.